Amlodipine maximum dosage

Pro Research Analysisby

Searched over 200M research papers

Analyzed relevant papers

Amlodipine Maximum Dosage in Hypertension and Heart Disease

Maximum Recommended Dosage of Amlodipine for Hypertension

Clinical studies have shown that amlodipine is effective in reducing blood pressure at doses ranging from 2.5 mg to 10 mg once daily. The maximum recommended daily dose for most patients with hypertension is 10 mg, as higher doses have not been shown to provide additional benefit and may increase the risk of side effects. In a double-blind trial, patients received up to 10 mg daily, and this was considered the highest effective and well-tolerated dose for blood pressure control . Another study comparing dose escalation found that increasing amlodipine from 5 mg to 10 mg daily provided further blood pressure reduction in patients not controlled on 5 mg, confirming 10 mg as the maximum standard dose .

Maximum Dosage in Coronary Artery Disease

In patients with coronary artery disease, intravenous amlodipine was studied at cumulative doses up to 20 mg, but the minimum effective intravenous dose was found to be 10 mg. This suggests that, even in this population, 10 mg is the typical maximum daily dose for clinical use .

Fixed-Dose Combinations and Maximum Dosage

Fixed-dose combination tablets containing amlodipine are available in strengths up to 10 mg, often combined with other antihypertensive agents such as olmesartan or valsartan. Pharmacokinetic studies confirm that amlodipine 10 mg in combination tablets is bioequivalent to 10 mg given alone, supporting the use of 10 mg as the maximum dose in combination therapies as well 46.

Safety and Tolerability at Maximum Dosage

Across studies, amlodipine at doses up to 10 mg daily was generally well tolerated, with side effects being mild to moderate in intensity. There were no significant effects on heart rate, electrocardiogram, or body weight at this dose .

Conclusion

The maximum recommended dosage of amlodipine for adults is 10 mg once daily, whether used alone or in combination with other medications for hypertension or coronary artery disease. This dose is effective, well tolerated, and supported by multiple clinical studies 12346.

Sources and full results

Most relevant research papers on this topic

Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension.

Amlodipine effectively reduces blood pressures with once-daily dosing, with 2.5 mg being the minimum effective dose, and is well-tolerated in patients with mild to moderate hypertension.

RCT

1988·

25citations

·Frick Mh et al.

A haemodynamic dose finding study with a new slow-calcium channel blocker (amlodipine) in coronary artery disease.

Amlodipine effectively reduces left ventricular afterload and enhances cardiac pumping performance in stable coronary artery disease patients, with a minimum effective i.v. dosage of 10 mg.

Non-RCT

1986·

19citations

·M. Frais et al.

An anchored simulated treatment comparison of uptitration of amlodipine compared with a low-dose combination treatment with amlodipine 5 mg/bisoprolol 5 mg for patients with hypertension suboptimally controlled by amlodipine 5 mg monotherapy

The low-dose combination of amlodipine 5 mg and bisoprolol 5 mg effectively reduces diastolic blood pressure in hypertensive patients, while no significant difference is seen in systolic blood pressure.

2022·

2citations

·C. Foch et al.

Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed‐Dose Combination

The fixed-dose combination of amlodipine and olmesartan is bioequivalent to amlodipine 10 mg plus olmesartan medoxomil 40 mg, with dose-proportional total exposure.

RCT

2008·

32citations

·S. Rohatagi et al.

Clinical Benefit of Fixed‐Dose Combination of Amlodipine and Potent Atorvastatin in Patients With Concomitant Hypertension and Hypercholesterolemia

A fixed-dose combination of amlodipine and high-dose atorvastatin reduces the risk of cardiovascular outcomes in patients with concomitant hypertension and hypercholesterolemia compared to free combination or lower dose atorvastatin.

Observational Study

2024·

2citations

·Chia-Pin Lin et al.

QUANTITATIVE ANALYSIS OF AMLODIPINE BESYLATE AND VALSARTAN IN TABLET DOSAGE FORM BY ABSORPTION FACTOR SPECTROPHOTOMETRY METHOD

This study developed a simple spectrophotometry method using methanol solvent to accurately determine amlodipine besylate and valsartan levels in tablet dosage forms without interference from excipients.

2022·

2citations

·S. M. Sinaga et al.

The Impact of Paediatric Obesity on Drug Pharmacokinetics: A Virtual Clinical Trials Case Study with Amlodipine

Obese children require a 1.25- to 1.5-fold increase in dose to achieve the same Cmax concentration as non-obese children when using a fixed-dose regimen.

Observational Study

2024·

1citation

·Khairulanwar Burhanuddin et al.

Amlodipine: a randomized, blinded clinical trial in 9 cats with systemic hypertension.

Amlodipine is an effective once-daily antihypertensive agent for cats when administered at a dosage of 0.18 +/- 0.03 mg/kg sid.

RCTAnimal StudyHighly Cited

1998·

76citations

·P. Snyder

Do more with less? Impact of personalized very low doses of amlodipine in the PERSONAL-CovidBP trial

Very low doses of amlodipine (1mg) effectively control blood pressure and are associated with fewer side effects, regardless of whether the patient is amlodipine naive or not at baseline.

2024·

0citations

·D. Collier et al.

Amlodipine Therapy in β-Thalassemia Patients: A Systematic Review and Meta-Analysis on Ferritin Levels and Liver MRI T2*

Amlodipine at a dose of 2.5 to 5 mg a day, up to a year, may improve serum ferritin levels and liver T2-weighted magnetic resonance imaging in -thalassemia patients.

Meta-Analysis

2023·

0citations

·Aily Aliasgharian et al.

Try another search

cancer causes and risk factors

artificial intelligence and deep learning

space shuttle program history

angiotensin receptor blockers for hypertension

is vitamin d a hormone

evolocumab clinical efficacy